

Top 200 Pharmaceutical Products by Worldwide Sales in 2008

Compiled and Produced by the Njardarson Group (Cornell University): Nicholas McGrath, Matthew Brichacek, Alexandra Plichta, Daniel J. Mack, Jón T. Njardarson

1 LIPITOR (Atorvastatin)  \$3658 Million CHOLESTEROL-LOWERING AGENTS	2 PLAVIX (Clopidogrel)  \$2635 Million PLATELET AGGREGATION INHIBITORS	3 NEXIUM (Esomeprazole)  \$2445 Million ANTI-REFLUX AGENTS	4 SERETIDE (Fluticasone & Salmeterol)  \$2706 Million B2-STIMULANT/STEROID COMBIS	5 ENBREL (Etanercept)  \$2703 Million SPECIAL ANTITUMOR AGENTS	6 SEROQUEL (Quetiapine)  \$2408 Million ANTI-PSYCHOTICS	7 ZYPREXA (Ezetimibe)  \$2329 Million ANTI-PSYCHOTICS	8 REMICADE (Infliximab)  \$4856 Million IMMUNOSUPPRESSIVE AGENTS	9 SINGULAR (Montelukast)  \$4741 Million ANTI-LEUKOTRIENE AGENTS	10 LOVENOX (Enoxaparin)  \$4440 Million HEPARINS	11 MABTHERA (Rituximab)  \$4338 Million ALL-OTH ANTINEOPLASTICS	12 TAKEPRON (Lacosamide)  \$4321 Million ANTI-EPILEPTICS	13 EFFEXOR (Venlafaxine)  \$4276 Million ANTIDEPRESSIVE & MOOD STAB.	14 HUMIRA (Adalimumab)  \$4075 Million SPECIAL ANTITUMOR AGENTS	15 AVASTIN (Bevacizumab)  \$4033 Million ALL-OTH ANTINEOPLASTICS	16 CRESTOR (Rosuvastatin)  \$3943 Million CHOLESTEROL-LOWERING AGENTS	17 RISPERDAL (Risperidone)  \$3899 Million ANTI-PSYCHOTICS	18 ACTOS (Pioglitazone)  \$3794 Million ORAL ANTIDIABETICS	19 NEULASTA (Pegfilgrastim)  \$3779 Million IMMUNOSTIMULATING AGENTS	20 HERCEPTIN (Trastuzumab) \$3764 Million ALL-OTH ANTINEOPLASTICS
---	---	---	--	---	--	--	---	---	---	--	---	---	--	---	--	---	---	---	---

Source: IMS MIDAS Review (TM), January 2008-December 2008. IMS Health Incorporated. All Rights Reserved. The information, findings, conclusions, views, and opinions contained and reported in the report are based on the data obtained under license from the following IMS Health Incorporated information services: IMS MIDAS Review (TM), January 2008-December 2008. IMS Health Incorporated. All Rights Reserved. IMS Health Incorporated. All Rights Reserved. Such statements, findings, conclusions, views, and opinions are not necessary a result of IMS Health Incorporated or any of its affiliated or subsidiary entities.